KEGG   DRUG: Salmeterol xinafoate and fluticasone propionateHelp
Entry
D08699            Mixture   Drug                                   

Name
Salmeterol xinafoate and fluticasone propionate;
Adoair diskus (TN);
Aerivio Spiromax (TN)
Product
  Generic
Component
Salmeterol xinafoate [DR:D00687], Fluticasone propionate [DR:D01708]
Class
Metabolizing enzyme substrate
 DG02913  CYP3A4 substrate
Remark
Therapeutic category: 2290
ATC code: R01AD58 R03AK06
Product: D08699<JP/US>
Efficacy
Antiasthmatic
  Disease
Asthma [DS:H00079]
Chronic obstructive pulmonary disease [DS:H01714]
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R01 NASAL PREPARATIONS
   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
    R01AD Corticosteroids
     R01AD58 Fluticasone, combinations
      D08699  Salmeterol xinafoate and fluticasone propionate <JP/US>
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03A ADRENERGICS, INHALANTS
    R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
     R03AK06 Salmeterol and fluticasone
      D08699  Salmeterol xinafoate and fluticasone propionate <JP/US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Bronchodilator Combinations
   Fluticasone Propionate/ Salmeterol
    D08699  Salmeterol xinafoate and fluticasone propionate
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D08699  Salmeterol xinafoate and fluticasone propionate
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08699
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D08699
BRITE hierarchy
Other DBs
PubChem: 96025382
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system